<div id="readability-page-1"><div><figure> 
 <img src="https://imageproxy.lbkrs.com/https://specials-images.forbesimg.com/imageserve/607d377b5795b113f88148de/960x0.jpg/query-Zml0PXNjYWxl" alt="Logo" original-src="https://specials-images.forbesimg.com/imageserve/607d377b5795b113f88148de/960x0.jpg?fit=scale"/> 
 
 <figcaption> 
 
 Logo 
 
 Prothena 
 </figcaption> 
</figure> 
The stock price of Prothena Corporation (NASDAQ: PRTA), a biotechnology company focused on treatment of diseases that involve protein misfolding or cell adhesion, has seen a 9% rise over the last five trading days, after the company announced that PRX004 phase 1 study results were selected for Emerging Science Oral Presentation at AAN 2021. PRX004 is an investigational anti-amyloid immunotherapy for the treatment of ATTR amyloidosis. Earlier in December 2020, the company announced positive results from early clinical trials for the treatment. The transthyretin amyloidosis market itself has a huge growth potential with estimated size of $14 billion in 2029, compared to a mere $0.6 billion in 2019. 
 
Looking at the recent rally, the 9% rise for PRTA stock over the last five days compares with a 2% rise seen in the broader S&amp;P 500 index. Now, is PRTA stock poised to rise further? It looks that way. The company’s pipeline surely is promising, and based on our machine learning analysis of trends in the stock price over the last few years, we believe that there is a 60% chance of a rise in PRTA stock over the next month (twenty-one trading days). 
Out of 296 instances in the last eight years that Prothena stock saw a five-day rise of 9% or more, 177 of them resulted in PRTA stock rising over the subsequent one month period (twenty-one trading days). This historical pattern reflects 177 out of 296, or about 60% chance of a gain in PRTA stock over the coming month. See our analysis on Prothena Corporation Stock Chances of Rise for more details. 
 
Five-Days: PRTA 9.2%, vs. S&amp;P500 2%; Outperformed market 
(14% likelihood event) 
 
 
<ul> 
 <li>Prothena Corporation plc stock rose 9.2% over a five-day trading period ending 4/15/2021, compared to broader market (S&amp;P500) rise of 2.0%</li> 
 <li>A change of 9.2% or more over five trading days is a 14% likelihood event, which has occurred 299 times out of 2086 in the last eight years</li> 
</ul> 
 
 
<figure> 
 
 
 <figcaption> 
 
 Five Day performance 
 
 Trefis 
 </figcaption> 
</figure> 
Ten-Days: PRTA 2.1%, vs. S&amp;P500 5.2%; Underperformed market 
(46% likelihood event) 
 
<ul> 
 <li>Prothena Corporation plc stock rose 2.1% over the last ten trading days (two weeks), compared to broader market (S&amp;P500) rise of 5.2%</li> 
 <li>A change of 2.1% or more over ten trading days is a 46% likelihood event, which has occurred 948 times out of 2081 in the last eight years.</li> 
</ul> 
 
While PRTA stock may continue to trend higher, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for United Therapeutics vs. D.R. Horton. 
See all Trefis Price Estimates and Download Trefis Data here 
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&amp;D, and Marketing Teams 
 
</div></div>

The stock price of Prothena Corporation, a biotechnology company focused on treatment of diseases that involve protein misfolding or cell adhesion, has seen a 9% rise over the last five trading days, after the company announced that PRX004 phase 1 study results were selected for Emerging Science...

What’s Next For Prothena Stock After A 9% Rise This Week?